Phase 3 Readout
RCUS: Phase 3 Topline: A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy
August 1, 2026 · domvanalimab. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 1, 2026
- Company
- Arcus Biosciences, Inc. (RCUS)
- Drug
- domvanalimab
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy
- Drug
- domvanalimab
- Indication
- Advanced Upper Gastrointestinal Tract Adenocarcinoma